Loading...

Invion Limited

IVX.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
A$0.10
A$0.003(3.13%)

Invion Limited (IVX.AX) Company Profile & Overview

Explore Invion Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Invion Limited (IVX.AX) Company Profile & Overview

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOThian Chew

Contact Information

61 3 9692 7222
100 Albert Road, Melbourne, VIC, 3205

Company Facts

8 Employees
IPO DateFeb 14, 2010
CountryAU
Actively Trading

Frequently Asked Questions

;